Danaher Corporation (DHR)
Summary
DHR Chart
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?
DHR's Q3 results are due Oct. 21, with growth in Biotechnology, Diagnostics and Life Sciences expected to boost revenues, while rising costs and currency headwinds weigh on earnings.
Seeking Clues to Danaher (DHR) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Danaher (DHR) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Danaher Corporation (DHR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Danaher Corporation ever had a stock split?
Danaher Corporation Profile
| Professional Services Industry | Industrials Sector | Julie Sawyer Montgomery CEO | XMEX Exchange | US2358511028 ISIN |
| US Country | 59,000 Employees | 31 Jul 2026 Last Dividend | 2 Oct 2023 Last Split | 5 Jan 1979 IPO Date |
Overview
Danaher Corporation is a global powerhouse in the design, manufacturing, and marketing of a vast array of professional, medical, industrial, and commercial products and services. With its inception in 1969 and a significant rebranding in 1984, where it transitioned from Diversified Mortgage Investors, Inc. to Danaher Corporation, the company has established a formidable presence in various sectors. Headquartered in Washington, D.C., Danaher stands out through its commitment to innovation, excellence, and enhancing the quality of life worldwide.
Products and Services
- Biotechnology: Danaher's biotechnology segment is a provider of bioprocess technologies, consumables, and services enhancing the development and manufacture of therapeutics. This includes cell line and cell culture media development, chromatography resins, filtration technologies, aseptic fill-finish solutions, single-use hardware, and comprehensive services aimed at setting up full manufacturing suites.
- Life Sciences: This segment delivers a wide range of products including mass spectrometers, flow cytometry, genomics solutions, lab automation instruments, centrifugation, liquid handling automation instruments, antibodies and reagents, particle counting and characterization tools, microscopes, and protein consumables. Among the notable brands under the Life Sciences segment are ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX, each providing specialized products for genomic medicines and industrial filtration.
- Diagnostics: Danaher’s diagnostics sector offers a comprehensive range of chemistry, immunoassay, microbiology, automation systems, molecular diagnostics, acute care, and pathology diagnostics products. Aimed at hospitals, physicians' offices, reference laboratories, and other critical care settings, this segment ensures the delivery of clinical instruments, reagents, consumables, software, and dedicated services to support critical diagnostics.
Contact Information
